FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/3/2026
Piper Jaffray maintained an Overweight rating on INSYS Therapeutics (NASDAQ: INSY), and cut the price target to $46.00 (from $49.00), following the company's 4Q earnings report. Insys reported adjusted diluted EPS of $0.36 on revenues of $91M, in-line with Street estimates. INSY is guiding to a sequential decline in Subsys sales in 1Q16, driven in significant part by the company no longer contracting with OptumRx. This is... More

